Lantern Pharma Inc.
3.8200-0.16 (-4.02%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · LTRN · USD
Key Stats
Market Cap
41.25MP/E (TTM)
-Basic EPS (TTM)
-1.78Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Lantern Pharma narrowed its Q2 operating loss to $4.7M, down 14% year-over-year from $5.4M, while research and development expenses dropped 21% to $3.1M amid efficient clinical progress on LP-300, LP-184, and LP-284. For the first half, the net loss improved 15% to $8.9M from $10.4M, with diluted EPS at -$0.82 versus -$0.97 last year, confirmed against 10.8M weighted shares showing no dilution effects. Cash burn eased, with operating cash use at $8.3M for the half, offset by $6.8M from marketable securities sales, leaving $15.9M in cash and equivalents at quarter-end to fund operations into June 2026. No debt burdens the balance sheet, but the ATM offering in July adds flexible liquidity. Yet funding remains tight for biotech trials.
8-K
Q2 results highlight clinical breakthroughs
Lantern Pharma reported Q2 2025 financials, posting a net loss of $4.33 million on $15.9 million cash, enough to run operations into June 2026. Clinical wins shone: LP-184 wrapped Phase 1a enrollment in 65 patients, setting up Phase 1b/2 trials in TNBC and bladder cancer; LP-300 notched a complete response in advanced NSCLC; LP-284 delivered one in refractory DLBCL. RADR® platform launched PredictBBB.ai for CNS drugs and a combo prediction module. Yet cash burn persists amid trial risks.
8-K
Board adds biotech expert
Lantern Pharma bolstered its board on July 24, 2025, appointing Lee T. Schalop, M.D., a biotech veteran who co-founded Oncoceutics—sold for $450 million—and brings 19 years of Wall Street experience. This move adds deep expertise in drug development and finance to guide strategic growth. The board also eased quorum rules to one-third of shares, streamlining stockholder meetings. Savvy hire for navigating oncology challenges.
8-K
ATM agreement for $15.5M stock sales
Lantern Pharma Inc. entered an ATM Sales Agreement with ThinkEquity LLC on July 3, 2025, enabling sales of up to $15.5 million in common stock at prevailing market prices. The deal pays the agent a 3.0% commission and can terminate at the company's discretion with 10 days' notice. This flexible funding avenue bolsters Lantern's capital access amid biotech demands. Yet risks include market volatility impacting proceeds.
10-Q
Q1 FY2025 results
Lantern Pharma narrowed its Q1 operating loss to $4.8M from $5.7M a year ago, driven by a 23% drop in R&D spending to $3.3M as LP-184 clinical costs eased, while G&A held steady at $1.5M. Net loss improved to $4.5M ($0.42 per share) from $5.4M ($0.51), with interest income at $150K offsetting some expenses; EPS aligns with 10.8M diluted shares, no anti-dilution noted. Cash burn quickened to $4.4M from operations, yet liquidity stands solid at $20.8M in cash and marketable securities, funding runway past 12 months without debt. R&D tax incentives from the Australia subsidiary added a small lift. Progress feels steady. But clinical trial delays could stretch that runway thin.
IPO
Employees
Sector
Industry
BOLT
Bolt Biotherapeutics, Inc.
5.86+0.14
CLRB
Cellectar Biosciences, Inc.
3.35+0.04
KURA
Kura Oncology, Inc.
10.26-0.25
LITS
Lite Strategy, Inc.
2.08+0.15
MNPR
Monopar Therapeutics Inc.
84.16+4.24
ORIC
Oric Pharmaceuticals, Inc.
12.93-0.50
OTLC
Oncotelic Therapeutics, Inc.
0.10+0.00
RENB
Lunai Bioworks Inc.
1.42+0.00
SEPN
Septerna, Inc.
21.94-0.38
TERN
Terns Pharmaceuticals, Inc.
8.02-0.57